Amarin Corp Plc (AMRN)

[jessellivermore]

John King...

Quote ACC CVOT results...Evolacumab (PCSK9 inhibitor)

Interpretation:

Among patients with elevated cardiovascular risk on statin therapy, evolocumab versus placebo was effective at reducing adverse cardiovascular events. Evolocumab was associated with marked reductions in LDL-C levels. Serious adverse events were similar between treatment groups. Efficacy for evolocumab was similar among those with very low baseline LDL-C levels. There was a greater absolute reduction in major adverse events for evolocumab versus placebo among those with the highest baseline inflammatory risk and genetically determined high-risk status. PCSK9 inhibition represents a novel approach to lower LDL-C levels and improves cardiovascular outcomes. However, for the duration of follow-up, there was no benefit on cardiovascular or all-cause mortality, and cost remains an issue.

The treatment of heart disease is like "affirmation" you repeat a 1000 times "I believe I can do it"..Then on 1001 you say "no". The treatment of atherosclerosis has been under the guidance of cardiologists and lipidolgist for the past century and they have focused lipid levels and it is becoming more and more obvious they should be focusing on Systemic Inflammation (SI)..Blood markers such as trigs, sugar, and likely LDL-C reflect the SI and the R-I trial even though the cardiolgist (including Bhatt) have refused to consider the Inflammatory levels related to changes in the EPA/AA ratios (something we have not heard about) R-I's legacy will be its confirmation that elevated SI is the root cause of cardiovascular disease and is the "puppet master" and the blood markers are only the puppets..

Right now I would much rather be holding the deed to Vascepa rather than any drug that merely lowers blood lipids unless it is doing it by lowering SI...

":>) JL